|Renamed Tokyo office as Tokyo head office
|UMN-0501, UMN-0502, UMN-0901: license agreement with Protein Sciences Corporation
|Establishment of Akita laboratory
|UMN-0501: land in Akita acquired as future site of vaccine manufacturing facility
|UMN-0501: received orphan drug designation by the Japanese Ministry of Health, Labour and Welfare
UMN-0501: initiation of phase I/II trials
|UMN-0501: preparations for construction of UMN Pharma's vaccine manufacturing facility in Akita
|Relocated Tokyo head office to Yokohama and named as Yokohama Headquarters
|UMN-0501: favorable immunogenicity and tolerability observed in phase I/II trial
|Establishment of Yokohama laboratory
|Formed partnership with IHI corporation
|Formed partnership with API Co., Ltd.
|Establishment of UNIGEN Inc.
|Entered into the license agreement for UMN -0501 and UMN-0502 with Astellas Pharma Inc.
|UMN-05: license agreement for China, Korea, Taiwan, Hong Kong and Singapore with Protein Sciences Corporation.
|Establishment of Akita Plant
|UMN-0502 (ASP7374): initiation of phase I/II trials
|UMN-0501 (ASP7373): initiation of phase II trial
|UMN-0502 (ASP7374): favorable immunogenicity and tolerability observed in phase I/II trial
|UMN-2003: license agreement with Dr. Timo Vesikari and Dr. Vesna Blazevic of the University of Tampere Vaccine Research Center
|UNIGEN Selected in First Round of METI's FY 2011 “Subsidy for Domestic Location Promotion Projects”
|Commencement of construction of UNIGEN's manufacturing facility in Gifu
UMN-0501 (ASP7373): immunogenicity and favorable tolerability observed in phase II trial
|UNIGEN Designated as Gifu Prefectural Government's “Subsidy for Promotion of Establishment of New Business Facilities”
|Listed on Tokyo Stock Exchange Mothers market
UMN-0502 (ASP7374): administration completed in phase III trial
Entered into the license agreement for UMN-0501, UMN-0502 and UMN-0901 with ILDONG Pharmaceutical Co., Ltd.
|UMN-0502 (ASP7374): Non-inferiority observed in phase III trial among 1,060 elderly volunteers.
|Relocated Yokohama Headquarters to Minato Mirai in Yokohama
|Formed partnership for Co-development and commercialization biosimilars in the field of Oncology with YakultHonsha Co., Ltd. and API Co., Ltd
|UMN-0502 (ASP7374): Non-inferiority observed in phase III trial among 900 healthy volunteers aged from 20 to 64 years.
|Entered into the collaborative research agreement for norovirus vaccine with DAIICHI SANKYO COMPANY, LIMITED.
|UMN-0502(ASP7374): submitted an application for marketing approval in Japan
|Relocated Yokohama Headquarters to Shin-Yokohama in Yokohama
|Formal agreement between UNIGEN Co., Ltd., and Protein Sciences Corporation on the supply of active pharmaceutical ingredients for seasonal recombinant influenza vaccine Flublok®
|Basic agreement with Protein Sciences Corporation for a vaccine development consortium against Zika virus infection
|Transitioned from an exclusive commercialization rights license agreement for a norovirus/rotavirus combination vaccine to a non-exclusive commercialization rights license agreement for a norovirus vaccine alone
|Received to Astellas Pharma Inc.’s offer to exercise the right to terminate the joint business agreement for ASP7374 (UMN-0502) and ASP7373 (UMN-0501)
Transferred all shares of our consolidated subsidiary, UNIGEN Co., Ltd.
Terminated the basic agreement with IHI Corporation for collaboration in the UMN-0502 and UMN-0501 drug substance manufacturing business
|Agreed to terminate the joint business agreement with Astellas Pharma Inc. concerning ASP7374 (UMN-0502) and ASP7373 (UMN-0501)
Withdrawal of the orphan drug designation of UMN-0501
Agreed to terminate the joint business agreement on antibody biosimilars in the oncology field between API Co., Ltd. and Yakult Honsha Co., Ltd.
|Decreased the amount of capital and capital reserve. and disposed of the surplus
|Joint research agreement on new adjuvants with the National Institute of Biomedical Innovation, Health and Nutrition
|Agreed to terminate the joint research contract with DAIICHI SANKYO COMPANY, LIMITED for norovirus vaccines
Concluded a capital and business alliance agreement with Shionogi & Co., Ltd.
Issued new shares and 1st unsecured convertible bonds with stock acquisition rights (1st CB) through third-party allotment to Shionogi & Co., Ltd.
|Expanded the scope of joint research on new adjuvants with the National Institute of Biomedical Innovation, Health and Nutrition
Agreed to terminate the license agreement for influenza vaccines in Japan and East Asia with Protein Sciences Corporation
|Agreed to terminate the basic agreement with Protein Sciences Corporation regarding a vaccine development consortium for Zika virus infection
Increase in the amount of capital and the amount of capital reserve due to partial conversion of 1st CB through third-party allotment to Shionogi & Co., Ltd.
|Shionogi & Co., Ltd. announced a tender offer for the Company's shares
|Completed a tender offer for the Company’s shares by Shionogi & Co., Ltd., which made the Company a subsidiary
|Delisted from Tokyo Stock Exchange Mothers due to procedures for becoming a wholly owned subsidiary of Shionogi & Co., Ltd.
Shionogi & Co., Ltd. entered the infectious disease prevention vaccine business by making our company a wholly owned subsidiary
|Relocated Yokohama Headquarters to Tokyo and named as Tokyo Headquarters